{"id":12750830,"date":"2024-11-20T08:49:08","date_gmt":"2024-11-20T13:49:08","guid":{"rendered":"https:\/\/www.philstockworld.com\/?p=12750830"},"modified":"2025-02-27T13:10:19","modified_gmt":"2025-02-27T18:10:19","slug":"watch-list-wednesday-bargain-hunting-for-2025-members-only","status":"publish","type":"post","link":"https:\/\/www.philstockworld.com\/2024\/11\/20\/watch-list-wednesday-bargain-hunting-for-2025-members-only\/","title":{"rendered":"Watch List Wednesday &#8211; Bargain Hunting for 2025 (Members Only)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"https:\/\/d3mjb9ojo74ap1.cloudfront.net\/wp-content\/uploads\/2022\/12\/Who_Watches_the_Watchmen1.jpg\" alt=\"Who_Watches_the_Watchmen\" width=\"351\" height=\"161\" \/><strong>We&#8217;re looking for our 2025 Trade of the Year.\u00a0\u00a0<\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.philstockworld.com\/2024\/07\/10\/watch-list-wednesday-second-half-of-2024-members-onl\/\" target=\"_blank\" rel=\"noopener\">Our last Watch List was published on July 10th<\/a>, following up on our main list <\/strong>(like this one)<strong> <a href=\"https:\/\/www.philstockworld.com\/2023\/12\/27\/watch-list-wednesday-trade-ideas-for-2024-and-beyond\/\" target=\"_blank\" rel=\"noopener\">from Dec 27th, 2023<\/a> and now it&#8217;s time to take a long hard look at what stocks are still buyable &#8211; and it&#8217;s going to be a short list this year, for sure! The S&amp;P was kissing 4,800 in December and 5,200 in July but now we&#8217;re at the 6,000 line &#8211; up 25% for the year!<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-12750831\" src=\"https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024.png\" alt=\"\" width=\"1565\" height=\"1157\" srcset=\"https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024.png 1565w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-300x222.png 300w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-1024x757.png 1024w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-768x568.png 768w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-1536x1136.png 1536w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-150x111.png 150w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-485x360.png 485w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-696x515.png 696w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2024\/11\/SPX-Nov-20-2024-1068x790.png 1068w\" sizes=\"auto, (max-width: 1565px) 100vw, 1565px\" \/><\/p>\n<p>Keeping in mind that 8% is a &#8220;normal&#8221; market year &#8211; that&#8217;s 3 years worth of gains in 11 months and yes, we did do that from 2020 to 2022 but that was 21 months and involved $11Tn in stimulus to get us there and we STILL pulled back from 4,800 to 3,600 (25%) in 2022 and this run hasn&#8217;t pulled back at all &#8211; yet. That makes it a LOT harder to pick winners for the next 12 months.\u00a0\u00a0<\/p>\n<p>When we add a stock to one of our Member Portfolios, it generally begins with the sale of a put, to give us an even lower net entry price (see \u201c<em><a href=\"https:\/\/youtu.be\/pYWQ3sNK9qA?si=tOSS1T1Ak4cm2AWW\" target=\"_blank\" rel=\"noopener\">How to Buy a Stock for a 15-20% Discount<\/a><\/em>\u201c) and then we build a position from that over time (see our\u00a0<a href=\"https:\/\/www.philstockworld.com\/strategy\/\" target=\"_blank\" rel=\"noopener\">Strategy Section<\/a>). With the entire S&amp;P 500 up 20% since December, bargains are certainly harder to find \u2013 but they\u2019re out there\u2026\u00a0<\/p>\n<p><strong>For our Watch List, we look for Blue-Chip type companies with low debt, low p\/e and reasonable anticipated growth.\u00a0 I\u2019m including legacy prices in the descriptions (<\/strong>in the brackets<strong>), so we\u2019ll know at what price we began watching\u00a0 \u2013 regardless of the date we began.<\/strong><\/p>\n<p>We&#8217;re going to start with what worked and what didn&#8217;t in 2024 and THEN we&#8217;ll move onto the macro view and THEN we&#8217;ll move on to the analysis and, HOPEFULLY, we&#8217;ll be done with this post around Thanksgiving &#8211; so expect to come back frequently for updates&#8230;<\/p>\n<p>We&#8217;re starting off with a review of last year&#8217;s picks because those who forget the past are condemned to repeat it &#8211; though 2024 was a fantastic year for our portfolios, so maybe we should skip this step? But we can&#8217;t because this list will lead to new picks, etc &#8211; it&#8217;s the great circle of investing:<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>ARCB ($111.21)<\/strong><\/span>\u00a0&#8211; Currently demonstrating impressive value with a forward P\/E of 13.84x and strong earnings potential. Their logistics and transportation solutions business shows consistent growth with $405.68M in earnings. Trading well below sector averages while maintaining solid operational metrics, ARCB&#8217;s integrated logistics platform and focus on premium services suggest significant upside potential. Their asset-light model and strategic positioning in specialized transport provide clear catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=arcb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>ANF ($149.68)<\/strong><\/span> &#8211; Currently demonstrating impressive performance with Q2 2025 net sales up 21.2% year-over-year to $1.13B and net income growing 134.1%. Their omnichannel strategy and strong EBITDA margin of 17.51% (55.3% above industry average) show operational excellence. Trading at reasonable valuations given their growth rate, ANF&#8217;s strategic positioning in global markets and strong free cash flow generation suggest continued momentum through 2025 and currently trading at 14x. First time I&#8217;ve likely them in more than 10 years!<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=anf&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>APD ($260) \u2013 Currently at $328 (up 42% from our addition), with a $70Bn market cap. Q4 2024 showed adjusted EPS of $3.56, marking a 13% rise, and they completed the $1.81Bn LNG business sale to Honeywell<span class=\"whitespace-nowrap\">.<\/span>\u00a0Their adjusted EBITDA margin improved by 460 basis points, demonstrating continued operational excellence<span class=\"whitespace-nowrap\">.<\/span> However, at current prices, they&#8217;re trading at 18.23x earnings, which is starting to look expensive<span class=\"whitespace-nowrap\">.<\/span> While their core industrial gases business remains strong and their clean hydrogen projects are progressing (Neom project is 60% complete with 35% of production under contract), the significant price appreciation since July suggests waiting for a better entry point <span class=\"whitespace-nowrap\">.<\/span> The stock has likely gotten ahead of itself in the near term.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=apd%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>ARCC ($18) \u2013 Now at $21.83, ARCC continues to deliver solid performance with Q3 2024 GAAP EPS of $0.62, beating estimates<span class=\"whitespace-nowrap\">.<\/span>\u00a0The quarterly dividend remains steady at $0.48 (8.8% yield), and their portfolio investments have grown to $25.9Bn from $22.9Bn at the end of 2023<span class=\"whitespace-nowrap\">.<\/span>\u00a0Their conservative investment approach and highest BDC sector ratings from S&amp;P and Fitch demonstrate their continued strength<span class=\"whitespace-nowrap\">.<\/span>\u00a0Trading at a reasonable valuation with a stable dividend, ARCC remains an attractive investment, particularly given their proven ability to navigate varying interest rate environments. <strong><span style=\"color: #0000ff;\">Still a strong buy at current levels<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=arcc%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BA ($190) \u2013 Currently at $145, BA has resolved its labor issues with the November 4th agreement that gives machinists a 38% wage increase over four years, bringing average annual salaries from $75,608 to $119,309. However, Q3 2024&#8217;s core loss per share of $10.44 and $6.2Bn cash burn remain concerning. While production has resumed as of November 12th, the company faces significant challenges in ramping operations back to normal levels. The strike&#8217;s estimated $9.7Bn impact on Boeing and its suppliers will affect near-term performance. Even at this lower price point, Boeing remains speculative without clear evidence of operational improvement or consistent profitability. The resolution of labor issues removes one uncertainty, but quality concerns and production delays continue to plague the company. This remains a &#8220;watch and wait&#8221; situation until Boeing demonstrates sustainable operational improvements but <strong><span style=\"color: #0000ff;\">their 7-year backlog of orders is always a reason we look to invest (and they are in our LTP)<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ba%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>BAX ($33.48)<\/strong><\/span>\u00a0&#8211; Currently showing mixed performance with Q3 2024 results leading to trimmed guidance of $2.90-2.94 EPS for the full year. However, their strategic transformation program and improving operational efficiency show promise. Trading at attractive multiples with strong emerging market potential and significant contract renewals approaching in 2025, BAX offers compelling value. Their focus on core healthcare products and cost management initiatives position them well for margin expansion in 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=bax&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BBY ($74.50) \u2013 Currently at $87.02, BBY just reported mixed Q3 2024 results with revenue declining 8% to $9.7Bn and comparable sales falling 6.9%. They&#8217;ve lowered their FY2024 guidance, now expecting revenue of $43.1-43.7Bn (down from $43.8-44.5Bn) and comparable sales declining 6.0-7.5% (worse than previous -4.5-6.0% forecast). <strong><span style=\"color: #0000ff;\">However, adjusted EPS of $1.29 beat estimates of $1.19, and their 15x P\/E with a strong dividend yield still makes them relatively attractive<\/span><\/strong>. The market seems to be pricing in continued pressure from online competition, but their service-oriented approach and immediate fulfillment capability remain competitive advantages. Worth watching but proceed with caution given the lowered guidance.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=bby%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BCS ($7.81) \u2013 Trading at $13.08, BCS has shown strong momentum with Q3 profit before tax up 18% to \u00a32.23Bn and a solid RoTE of 12.3%. Their commitment to return \u00a310Bn to shareholders through 2026 remains on track, and they&#8217;ve upgraded their NII guidance for 2024 to greater than \u00a311Bn. At 9.28x earnings, the stock remains notably undervalued for a major financial institution, especially given their \u00a330Bn revenue target by 2026 and improving operational metrics. The successful integration of Tesco Bank (finalizing this month) should further strengthen their UK retail banking position BUT, as with all mergers &#8211; there&#8217;s bound to be a bit of pain. <strong><span style=\"color: #0000ff;\">Still appears significantly undervalued but no hurry.<\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=bcs%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BXMT ($22.25) \u2013 Now at $18.65, BXMT has shown significant progress in addressing portfolio concerns, reporting $1.0Bn in loan repayments and $0.4Bn in non-performing loan resolutions this quarter. They have an additional $1.0Bn of non-performing loan resolutions in closing, representing over 60% of total non-performing loans as of September 30, 2024. While Q3 showed a net loss of $56M, their distributable EPS of $0.39 and current dividend of $0.47 reflect ongoing operational stability. The recent resolution progress at or above carrying values suggests their portfolio quality is better than market fears implied. <strong><span style=\"color: #0000ff;\">With $1.5Bn in liquidity and improving market conditions, their position looks increasingly stable<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=bxmt%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CAKE ($31.50) \u2013 Currently at $46.57 (up 48% from our initial watch price), CAKE has shown impressive momentum with Q3 2024 revenues reaching $865.5M and net income of $30.0M ($0.61 per share). Trading at about 14x forward earnings with a 2.32% dividend yield, the stock has benefited from strong execution and expansion, with 22 new restaurant openings in 2024. Their diversification strategy and ability to maintain margins despite inflation pressures has proven successful. <strong><span style=\"color: #0000ff;\">While the significant price appreciation suggests caution, their operational performance continues to justify the higher valuation<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=cake%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>CALM ($97.61)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals as the largest producer of fresh shell eggs in the United States. Their integrated operations and focus on premium categories (cage-free, organic, pasture-raised) provide pricing power and margin expansion opportunities. Trading at attractive multiples with a solid balance sheet and no long-term debt, CALM offers both value and growth potential. Their strategic shift toward higher-margin specialty eggs and expanding production capacity positions them well for 2025 growth.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=calm&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CIM ($18.60) \u2013 Now at $14.75, CIM has rebounded nicely from earlier lows. Q3 2024 showed strong performance with GAAP earnings of $1.39 per share and a GAAP book value of $22.35 per share. Their strategic acquisition of Palisades Group and successful portfolio management, including $600M in new securities purchases, demonstrates improved stability. <strong><span style=\"color: #0000ff;\">Trading at a significant discount to book value with a more sustainable dividend yield, CIM appears better positioned than earlier in the year, though commercial real estate exposure still warrants careful monitoring<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=cim%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CLF ($16.20) \u2013 Trading at $11.44 (down significantly from our initial watch), CLF faces near-term challenges with Q3 2024 showing disappointing results including a $0.33 per share loss and revenues down 18% to $4.6B. However, their recent Stelco acquisition and projected $600M in annual EBITDA improvements from strategic initiatives could provide future catalysts. With reduced 2024 capex guidance of $600-650M and expected $70M in coal cost savings for 2025, <strong><span style=\"color: #0000ff;\">the current price might present an attractive entry point for patient investors betting on steel demand recovery in early 2025<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=clf%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>CMCSA ($43.29)<\/strong><\/span>\u00a0&#8211; Currently trading at 11.41x earnings with strong revenue growth across segments. Their Content &amp; Experiences segment showed 19% growth to $12.6B in recent quarters, while maintaining solid EBITDA margins. Trading at reasonable multiples with consistent execution, CMCSA&#8217;s diversified revenue streams and strategic positioning in streaming and broadband suggest continued momentum. Their focus on high-margin services and content creation provides multiple catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=cmcsa&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><strong>CNH <span style=\"color: #0000ff;\">($12.37)<\/span><\/strong> &#8211; Currently trading at 13.33x forward earnings and showing a 16% discount to Morningstar&#8217;s fair value estimate of $15.30. Their strategic refocus on higher-volume models and precision agriculture should improve manufacturing efficiency. Trading at attractive multiples with a 4.63% dividend yield, CNH&#8217;s operational streamlining and focus on core markets provide potential catalysts. Their reduced construction product lineup and emphasis on precision agriculture technology suggest stronger margins ahead.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=cnh&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CROX ($124) \u2013 Currently trading at $97.98, CROX has seen significant volatility since our initial watch. Q3 2024 earnings beat expectations with $3.60 EPS, topping estimates by $0.50. Their CFO&#8217;s recent purchase of 1,000 shares at $99.70 is an attempt to demonstrate insider confidence<span class=\"whitespace-nowrap\">.<\/span> With a market cap of $5.71B and a P\/E ratio of just 7.11, CROX appears significantly undervalued<span class=\"whitespace-nowrap\">.<\/span> While analysts have reduced price targets, the consensus remains bullish with an average target of $151.14, suggesting substantial upside potential<span class=\"whitespace-nowrap\">.<\/span> <strong><span style=\"color: #0000ff;\">At these levels, CROX presents an attractive value opportunity, particularly given their strong earnings performance mostly hobbled by the Hey Dude acquisition, which should work itself out over time<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=crox%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CRSP ($49) \u2013 Trading at $46.97, CRSP has experienced recent pressure with shares falling 6.6% in the past two weeks. However, their groundbreaking Casgevy therapy approval marks a significant milestone as the first CRISPR-based treatment. <strong>The company has activated more than 45 authorized treatment centers globally since mid-October, and early launch indicators are strong<\/strong>. While still unprofitable, with 2024 loss estimates improving just slightly from $5.58 to $5.20 per share, CRSP&#8217;s pipeline expansion into autoimmune diseases and solid tumors provides multiple growth catalysts. <strong><span style=\"color: #0000ff;\">Trading at a P\/B ratio of 2.06 (below industry average of 3.46), the stock offers an attractive entry point for long-term investors<\/span>.<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=crsp%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>CVS ($57.30)<\/strong><\/span> &#8211; Currently facing challenges with their health insurance business, leading to three guidance cuts in 2024. However, their integrated healthcare model, including pharmacy, benefits management, and insurance through Aetna, provides diverse revenue streams. Trading at 9.4x forward earnings with strong cash flow generation and strategic healthcare services expansion, CVS offers value at current levels. Their recent management changes and focus on operational efficiency suggest potential improvement in 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=cvs&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>DIS ($88) \u2013 At $112.42, DIS has shown steady upward momentum since early November, rising from the $96 range<span class=\"whitespace-nowrap\">.<\/span>\u00a0The stock has demonstrated consistent daily gains, with increasing trading volumes suggesting growing investor confidence<span class=\"whitespace-nowrap\">.<\/span>\u00a0Their streaming business achievements and recent box office successes provide strong fundamental support for the price appreciation. <strong><span style=\"color: #0000ff;\">While the DIRECTV disputes present a near-term challenge, the stock&#8217;s technical momentum and improving business metrics make it an increasingly attractive investment at current levels<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=dis%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>DOW ($51.88)<\/strong><\/span>\u00a0&#8211; Currently benefiting from favorable spreads between Brent oil and US natural gas prices, with 75% of production capacity in North America providing significant cost advantages. Their commodity chemical production is well-positioned for profit recovery in 2025, particularly as volume recovery continues through Q4 2024. Trading at attractive valuations with a narrow moat rating, DOW offers both value and potential catalyst-driven growth<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=dow&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>EPD ($33.81)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals in midstream energy services with attractive forward P\/E of 12.80x, below industry average. Their diversified portfolio across natural gas, NGLs, crude oil, and petrochemicals provides stable cash flows. Trading at compelling valuations with strong dividend coverage, EPD&#8217;s strategic positioning in natural gas infrastructure suggests continued growth as US consumption is projected to increase by 20 billion cubic feet per day by 2030.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=epd&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>ES ($63.67)<\/strong><\/span>\u00a0&#8211; Currently showing value after exiting offshore wind exposure, saving $2B in new equity needs over the next five years. Their $18B investment plan for 2024-27 focuses on electric and gas utilities supporting regional clean energy targets. Trading at a 7% discount to fair value with projected 6% annual earnings and dividend growth through 2026, ES offers an attractive combination of value and growth potential. Their return to core regulated utility operations reduces risk while maintaining strong growth prospects.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=es&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>EVRG ($63.61)<\/strong><\/span>\u00a0&#8211; Currently trading at one of the lowest P\/E ratios (16x) and highest dividend yields (4.2%) in the utility sector. Their $13B capital investment plan through 2028 looks conservative given announced developments from Alphabet, Meta, and Panasonic in their service territory. Trading at a significant discount to peers despite projected 6% annual earnings growth, EVRG offers both value and potential upside from increased capital spending plans. Recent positive legislative and regulatory developments provide additional catalysts.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=evrg&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>F ($11.63) \u2013 Currently at $11.06 (down from our initial watch price), Ford reported Q3 2024 adjusted EPS of $0.88, maintaining a reasonable P\/E of 12.56. Their market cap stands at $43.1B, with the stock trading below both 50-day ($10.81) and 200-day ($11.81) moving averages. While EV transition challenges persist, their traditional vehicle lineup, particularly the F-Series, continues to generate strong cash flow. The 4.8% dividend remains covered by earnings, but rising UAW labor costs and ongoing EV investments could pressure margins. <strong><span style=\"color: #0000ff;\">At current levels, F presents an attractive value proposition, though investors should monitor their EV market share progress and cash burn rate<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=f%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>FITB ($47.57)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals with projected long-term EPS growth of 12.6% and impressive return on equity of 12.5%. Their strategic positioning in key markets and focus on operational efficiency provide multiple growth drivers. Trading at compelling valuations with a 3.4% dividend yield, FITB&#8217;s technology investments and market share gains in commercial lending suggest stronger performance ahead. Their consistent execution and strong capital position provide catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=fitb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>FF ($4.06) \u2013 Trading at $5.20, FF has shown resilience with a P\/E of 6.34 and solid EPS of $0.82. Their market cap of $227.6M reflects their niche position in the renewable chemicals and biofuel space. Recent volume of 236,475 shares remains below the average of 297,331, suggesting steady but not speculative trading. The company&#8217;s strong balance sheet and history of special dividends continue to attract value investors, though these distributions can complicate options strategies. With biodiesel demand growing and chemical segment stability, FF offers an interesting small-cap opportunity, albeit with typical small-cap volatility risks.\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ff%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>FL ($27.79) \u2013 Now at $22.73, FL continues to face significant headwinds. Q2 2024 showed a return to topline growth with sales increasing 1.9% and comps rising 2.6%, but reported a loss of $0.13 per share. CEO Mary Dillon&#8217;s &#8220;Lace Up&#8221; strategic plan shows promise, with FY2024 guidance projecting total sales between -1% to +1% and comp sales growth of 1-3%. However, reduced Nike allocations and intense competition from JD Sports present ongoing challenges. The negative P\/E (-5.86) reflects recent struggles, but their strategic initiatives, including store optimization and enhanced FLX Rewards Program, could provide turnaround potential. While the stock appears cheap, execution risks remain high.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=fl%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>FMC ($54.88)<\/strong>\u00a0<\/span>&#8211; Currently trading at just 55% of fair value after significant pullback in 2024. Their agricultural sciences focus and planned divestiture of Global Specialty Solutions business should strengthen their balance sheet. While facing near-term challenges from patent expirations, their strong R&amp;D pipeline and expected profit rebound in 2025 make them attractive at current levels<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=fmc&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>GILD ($86) \u2013 Currently at $87.75, their Q3 2024 performance demonstrated strong fundamentals with a PE ratio that was skewed by one-time items and confused investors. With a market cap of $109.4B and trading above both its 50-day ($86.99) and 200-day ($74.95) moving averages, GILD shows strong technical momentum. Their HIV franchise remains robust, and their oncology pipeline continues to expand. <strong><span style=\"color: #0000ff;\">The current price level, while higher than our entry point, still offers value given their strong cash flow and dividend stability<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=gild%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>GNRC ($107) \u2013 Now at $179.94, GNRC has continued its impressive run, up 68% since our initial watch. The company&#8217;s focus on grid stability solutions and clean energy alternatives has proven prescient given increasing weather-related power disruptions. Trading at a PE of 37.49, the valuation has expanded but remains justified given their market leadership and growth prospects. Their expansion into clean energy solutions, particularly solar and battery storage, continues to drive growth. While no longer the bargain it was at $107, GNRC&#8217;s market position and execution make it worth holding, though new entries should be cautious at these levels.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=gnrc%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>GOLD ($20) \u2013 Trading at $17.72 (down from our watch price), Barrick recently reported Q3 2024 results showing steady performance with net earnings up 33% year-over-year and free cash flow of $444M, up 31% quarter-on-quarter. Their copper production increased 12% quarter-over-quarter, while maintaining steady gold production. The company continues its $1B share buyback program, having repurchased 4.725M shares in Q3, and maintains a $0.10 quarterly dividend. <strong><span style=\"color: #0000ff;\">With gold prices around $2,650, Barrick&#8217;s operational efficiency and cost management make it an attractive play on precious metals, especially at current levels<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=gold%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>HON ($212) \u2013 Currently at $228.20, HON has shown strong momentum since our initial watch. Q3 2024 results demonstrated solid execution with sales up 6% to $9.7B and adjusted EPS of $2.58, exceeding guidance. Their aerospace segment continues to lead growth, and the recent $1.9B CAES Systems acquisition strengthens their defense portfolio. The announced spin-off of their Advanced Materials business and exit from PPE shows strategic focus on core growth areas.\u00a0At current levels, HON&#8217;s premium valuation reflects their operational excellence and market leadership position.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=hon%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>IBM ($227.39)<\/strong><\/span>\u00a0&#8211; Currently showing strong momentum with their $3B AI consulting business and growing software revenue from WatsonX and Red Hat initiatives. Their upcoming z17 mainframe launch and strategic positioning in enterprise AI provide clear catalysts for 2025. Trading at attractive valuations with solid dividend yield, IBM&#8217;s transformation to a hybrid cloud and AI company suggests significant upside potential. Their consulting business growth and AI tailwinds provide multiple catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=ibm&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>IMAX ($19.75) \u2013 Trading at $24.90, IMAX has surged 26% from our initial watch price. The company&#8217;s strategy of programming more than 100 films and events annually has proven successful, with 2024 showing record box office numbers building on their strong 2023 performance of $1.06B globally.\u00a0Their continued expansion in international markets and ability to attract high-profile releases positions them well for continued growth through the holiday season and into 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=imax%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>IP ($37.40) \u2013 Now at $57.84, IP has shown remarkable appreciation since our watch price. Q3 2024 showed solid performance with net earnings of $150M ($0.42 per share) and strong cash flow of $521M. Their Industrial Packaging segment delivered $197M in operating profit, while Global Cellulose Fibers improved to $40M. The upcoming DS Smith transaction in early 2025 could be transformative. Despite higher operating costs and some volume challenges, IP&#8217;s pricing power and strategic initiatives position them well for continued growth. The company&#8217;s commitment to shareholder returns remains strong, having returned $161M in dividends during Q3.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ip%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>IVZ ($19.60) \u2013 Currently at $17.27, IVZ has shown resilience with Q3 2024 results revealing record-high AUM of $1.8 trillion and impressive net long-term inflows of $16.5B. Their adjusted operating margin improved to 31.6%, though Q3 GAAP earnings were impacted by a one-time $147.6M expense from changes to retirement vesting criteria. The quarterly dividend remains steady at $0.205 (4.6% yield), though some analysts express concern about sustainability given recent earnings volatility. With zero balance on their credit facility and over $1B in cash, their balance sheet remains strong. <strong><span style=\"color: #0000ff;\">While trading at a negative current P\/E due to recent charges, the company&#8217;s strategic position and growing AUM suggest potential upside<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ivz%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>JACK ($72) \u2013 Now at $46.03, JACK reports Q4 2024 earnings after today&#8217;s close. Analysts expect EPS of $1.09, representing 2.8% year-over-year growth. The stock has struggled, down 34.64% over the past 52 weeks due to increasing wages in CA, where they mainly operate. Their menu innovation and digital enhancements show promise, but inflationary pressures and changing consumer spending habits, particularly among budget-conscious customers, continue to impact performance. The company&#8217;s expansion plans and operational efficiency initiatives provide potential catalysts, but near-term headwinds suggest caution ahead of earnings &#8211; <strong><span style=\"color: #0000ff;\">though I do love them long-term<\/span><\/strong>.\u00a0\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=jack%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>JWN ($16.50) \u2013 Trading at $22.67 (up 37% from our initial watch), JWN has shown impressive momentum with a P\/E of 13.1 and EPS of $1.73. The company reports Q3 earnings next week (November 26), with the market clearly anticipating positive results given the recent price appreciation. Their focus on the luxury segment continues to provide resilience, though broader retail challenges persist. The stock&#8217;s technical performance, trading above both 50-day ($22.75) and 200-day ($21.21) moving averages, suggests sustained momentum.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=jwn%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>KELYA ($14.73)<\/strong><\/span>\u00a0&#8211; Currently showing strong value metrics with a forward P\/E of 12.59x, significantly below the industrial sector average of 23.52x. Their staffing and workforce solutions business benefits from current labor market dynamics and increasing demand for flexible workforce solutions. Trading at attractive valuations with solid fundamentals, KELYA&#8217;s strategic positioning in professional and technical staffing provides multiple growth catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=kelya&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>KLG ($11.75 \u2013 New symbol) \u2013 Currently at $17.20, KLG has shown impressive momentum since its spin-off, with Q1 2024 results beating adjusted EPS expectations despite a 0.8% YoY sales decline. Their adjusted EBITDA reached $75M (up 13.6% YoY) with margins improving 310 basis points to 7.5%. The company remains on track for their 14% adjusted EBITDA margin target by 2026. With strong brands like Frosted Flakes and Rice Krispies leading growth, and trading at 22x earnings with a $0.16 quarterly dividend, KLG offers an attractive mix of value and growth potential. The recent performance validates the spin-off strategy.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=klg&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>KHC ($36) \u2013 Trading at $30.58, KHC has adjusted its FY24 outlook due to inflationary pressures in coffee and dairy. However, their foodservice innovation strategy shows promise, with new time-saving dispensers driving incremental revenues. The segment, representing 14% of sales, is positioned for acceleration in 2025. Their EPS estimates of $3.01-3.04 for FY24 and $3.06-3.20 for FY25 suggest steady growth. While facing near-term challenges, <strong><span style=\"color: #0000ff;\">KHC&#8217;s focus on operational efficiency and foodservice innovation provides potential upside<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=khc%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>KMB ($139.35)<\/strong><\/span> &#8211; Currently showing better value after a pullback with strong fundamentals in essential paper products. Their cost-reduction initiatives and focus on premium products position them well for margin expansion in 2025. Trading at attractive multiples with solid dividend yield, KMB&#8217;s strategic repositioning and operational efficiency programs provide potential catalysts. Their emerging market growth and product mix improvements suggest stronger performance ahead.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=kmb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>KO ($63.85) \u2013 Now at $62.59, KO continues to demonstrate strong execution with Q3 2024 showing resilience despite a 1% volume dip. The company raised full-year guidance to 10% organic revenue growth and 14-15% comparable currency-neutral EPS growth. North American performance remains robust, particularly in trademark Coca-Cola products. With Wall Street&#8217;s average price target at $76.07 (range $65.65-$89.25) and strong cash flow generation, KO maintains its position as a defensive stalwart despite premium (21x) valuation. \u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ko%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LABU ($100) \u2013 Currently at $103.39 (up 4% yesterday!), this leveraged ETF continues to show high volatility with a 52-week range of $66.80-$176.99. Trading volume has increased to 1.54M shares versus the average of 988K, suggesting growing interest. While the biotech sector shows promise, particularly with breakthrough therapies and FDA approvals, the 3x leverage makes this extremely risky. <strong><span style=\"color: #ff0000;\">The ETF has underperformed its target due to the inherent decay in leveraged products<\/span><\/strong>. This remains a highly speculative play best suited for short-term trading rather than long-term holding and will be removed from this list.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=labu%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LEVI ($16.80) \u2013 Trading at $15.99, LEVI has faced challenges with Q3 2024 showing mixed results. The company is exploring strategic options for its underperforming Dockers brand, which saw a 15% decline in sales. However, their core denim business grew 5%, and direct-to-consumer revenues increased 16% with strong performance in both brick-and-mortar and eCommerce. While near-term holiday quarter guidance suggests caution, their strategic shift toward D2C and focus on core strengths could provide long-term value. <strong><span style=\"color: #0000ff;\">The current valuation at 42x earnings keeps people away but forward p\/e is more like 12 &#8211; so I still like them very much<\/span><\/strong>.\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=levi%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LFWD (6.40 \u2013 used to be RWLK) \u2013 Now at $1.84, LFWD continues to face significant challenges. The company recently appointed Robert J. Marshall Jr. to their Board as Audit Committee chair, bringing valuable financial leadership experience from Lantheus Holdings and Zimmer Biomet. While this strengthens corporate governance, the stock remains highly speculative. With a market cap of just $16.2M and negative earnings (-$2.23 per share), the company needs to demonstrate significant revenue growth to justify even current valuations. The recent board addition suggests a focus on financial oversight, which could be crucial for future capital raising efforts but now, <strong><span style=\"color: #ff0000;\">with Team Trump, it&#8217;s very unlikely the government will approve systems designed to help people walk again for Medicare <\/span><\/strong><span style=\"color: #ff0000;\">(not when wheelchairs are 1\/10h the price)<\/span><strong><span style=\"color: #ff0000;\"> &#8211; and that&#8217;s going to kill them<\/span><\/strong>.\u00a0\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=lfwd&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LOVE ($26.60) \u2013 Currently at $33.03 (up 24% from our initial watch), LOVE reported Q2 FY25 net sales growth of 1.3% to $156.6M, beating estimates. Internet sales grew 7% while showroom sales increased 0.6%. However, net loss widened to $5.9M ($0.38 per share) compared to $0.6M ($0.04 per share) in the prior year. Operating expenses increased 7.9% to $100.7M, primarily due to higher SG&amp;A costs. While their innovative product line and omnichannel strategy show promise, the significant increase in operating expenses warrants caution. The company maintains strong gross margins at 59%, but increasing costs are pressuring profitability. If they do get them under control &#8211; this could be a powerhouse.\u00a0\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=love%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LVS ($52.50) \u2013 Trading at $49.18, LVS continues to benefit from Macau&#8217;s tourism recovery and strong Singapore performance. Marina Bay Sands remains a significant revenue driver, while Macau&#8217;s economy shows its fastest expansion in over a decade. Despite these positive catalysts, the stock trades at a more attractive valuation than when we first watched it. Their diversified portfolio across Macau and Singapore provides some insulation against regional economic fluctuations. The recent price stabilization suggests the market is finding a balance between growth prospects and macro concerns.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=lvs%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MDT ($91) \u2013 Now at $85.00, MDT has shown strong momentum with Q1 FY25 revenue rising 5.3% organically to $8B. Their cardiovascular segment grew 6.9% to $3B, while diabetes sales jumped 12.6% to $647M. The recent FDA approval of Simplera\u2122 CGM and strategic partnership with Abbott strengthen their diabetes care portfolio. Trading at a P\/S ratio of 3.55 (below the industry average of 4.1), MDT appears undervalued. Their market leadership position and continuous innovation in key medical device segments support long-term growth potential.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mdt%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MGM ($38) \u2013 Currently at $36.79, MGM reported strong Q3 2024 results with revenue of $4.18B (up 5.3% year-over-year), though slightly missing estimates of $4.21B. EPS came in at $0.54, below consensus estimates of $0.58. Their Las Vegas operations continue to show strength, though Formula One bookings are softer compared to last year&#8217;s inaugural race. The 2023 cyberattack is well behind them, with systems fully restored and enhanced security measures in place. Trading at a P\/E of 13.27 with a market cap of $11B, MGM maintains a solid position in both domestic and international markets, particularly with MGM China showing strong performance. While analyst price targets range from $47-56, recent insider selling (121,000 shares at $36.72) suggests caution at current levels.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mgm%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MIDD ($144) \u2013 Trading at $134.24, MIDD&#8217;s Q3 2024 showed challenging results with revenue declining 3.9% to $942.8M, missing analyst expectations by 5.4%. While net profit increased 5.1% to $114.2M, their EPS of $2.12 missed estimates by 8.2%. Looking forward, revenue is projected to grow at 3.5% annually over the next three years, outpacing the machinery sector&#8217;s expected 3.0% growth. Recent stock performance has been weak, with shares down 5.4% in the past week.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=midd%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MP ($21.67) \u2013 Now at $18.01, MP reported Q3 2024 results showing 20% year-over-year revenue growth to $62.9M, beating analyst estimates of $40.14M. They achieved record REO production of 13,742 metric tons (up 28% YoY) and record NdPr production of 478 metric tons (up 76% sequentially). However, they posted a net loss of $25.5M ($0.16 per share). Their Fort Worth facility is in final commissioning for metal production, with deliveries expected by year-end. <strong><span style=\"color: #0000ff;\">While current financials show losses, their strategic position in rare earth production remains significant<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mp%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MRNA ($185) \u2013 Currently at $37.33, MRNA has experienced a dramatic 80% decline from our initial watch price. Q3 2024 showed significant challenges with a loss of $5.81 per share and market cap shrinking to $14.36B. Their cash position has deteriorated to $6.8B against ongoing R&amp;D expenses. While their pipeline remains promising, particularly in personalized cancer vaccines and RSV programs, the collapse of COVID vaccine revenue (down 94% YoY) has severely impacted financials. The negative P\/E of -6.42 reflects current struggles, though their mRNA platform technology maintains long-term potential. The stock&#8217;s decline reflects both market skepticism about their ability to replace COVID revenues and broader biotech sector weakness.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mrna%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MT ($29) \u2013 Trading at $25.03, MT reported Q3 2024 operating income of $0.7B, showing resilience despite market challenges. Their strategic focus includes significant investments in growth projects and a commitment to return at least 50% of post-dividend free cash flow to shareholders. With a market cap of $20.72B and trading at a negative P\/E of -19.08 due to recent losses, MT faces near-term headwinds but maintains strong fundamentals. T<strong><span style=\"color: #0000ff;\">heir continued focus on decarbonization and sustainable development positions them well for future industry trends<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mt%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>NKE ($126) \u2013 Now at $72.81, NKE has declined significantly from our initial watch price. The company faces substantial headwinds with analysts projecting FY2025 earnings of $2.74 per share, representing a 30.63% decline, and revenue expected to fall 7.55% to $47.48B. Trading at a forward P\/E of 27.3 (premium to industry average of 15.94), <strong><span style=\"color: #ff0000;\">the stock appears expensive despite its decline<\/span><\/strong>. Recent performance shows continued weakness, with shares down 8.09% over the past month while the broader Consumer Discretionary sector gained 5.04%. Their upcoming earnings announcement on December 19, 2024, will be crucial for gauging recovery potential.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=nke%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>NLY ($17.60) \u2013 Currently at $19.46, NLY maintains a strong dividend yield of 13.2% with quarterly payments of $0.65 per share. Their negative EPS of -$0.08 and extremely high payout ratio of 1,249% raise concerns about dividend sustainability. However, their business model as a mortgage REIT benefits from the current interest rate environment. With a market cap of $10.9B and trading at -243x earnings (due to recent losses), investors should monitor their upcoming earnings announcement on February 5, 2025, for signs of improved profitability.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=nly%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>OLN ($56.40) \u2013 Trading at $40.73, OLN shows a P\/E of 32.32 with EPS of $1.26. The stock has declined significantly from our initial watch price, with shares down 27.8% YTD. Recent performance shows continued weakness, trading below both 50-day ($44.51) and 200-day ($49.19) moving averages. Their upcoming earnings announcement on January 23, 2025, will be crucial for gauging recovery potential in both their chlor alkali and Winchester ammunition segments.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=oln%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>PARA ($20.30) \u2013 Now at $10.47, PARA trades significantly below the proposed $15 per share buyout price, reflecting market skepticism about the deal&#8217;s completion. The Skydance merger, expected to close by Q3 2025, offers shareholders either $15 in cash (capped at $4.3B total) or shares in New Paramount. The deal values Class B shares at $15 and Class A at $23, with Skydance receiving 317 million newly issued Class B shares. Total consideration amounts to approximately $9.4B. The significant spread between current price and buyout value suggests either serious doubts about deal completion or potential regulatory hurdles. The merger aims to achieve $2B in annual synergies, with projected completion by Q3 2025. Our spread targets are $12.50 but it&#8217;s amazing we&#8217;re still nowhere close.\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=para%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>PFE ($25.48)<\/strong><\/span>\u00a0&#8211; Currently trading near 52-week lows, Pfizer faces headwinds from post-COVID revenue declines but maintains strong fundamentals. Their Seagen acquisition strengthens their oncology pipeline, while their cost reduction program targets $4B in savings. Trading at just 10x forward earnings with a healthy dividend yield, PFE offers significant value at these levels. Their projected 8-10% operational revenue growth (excluding COVID products) for 2025 and robust pipeline of 110 programs in development provide multiple catalysts for recovery.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=pfe&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>PG ($179.26)<\/strong><\/span> &#8211; Currently demonstrating operational excellence with strong pricing power across their premium brands. Their focus on high-end market offerings and strategic innovation in health, beauty, and household essentials provides steady growth. Trading at reasonable valuations with consistent earnings beats, PG&#8217;s market leadership and focus on premium segments offer defensive characteristics with growth potential. Their continued product innovation and emerging market expansion provide catalysts for 2025 but, at the moment, a bit high in the channel.\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=pg&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>RKT ($10.60) \u2013 Currently at $13.69, RKT has shown mixed performance with Q3 2024 results missing revenue expectations. Trading at a forward P\/E of 27.84, the stock appears expensive given current market conditions. Their market cap of $27.29B reflects their position as the largest mortgage originator, though high interest rates continue to pressure the housing market. While analysts maintain a &#8220;Sell&#8221; rating with a $15.23 price target, their technology platform and market leadership could provide upside if interest rates decline in 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=rkt%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>RH ($300) \u2013 Trading at $339.29, RH shows momentum with recent store expansion plans. Their Q2 2024 revenues reached $829.7M (up from $800.5M YoY), though earnings declined to $1.45 per share from $3.36. New store openings, including the 90,000-square-foot RH Newport Beach and RH Raleigh, demonstrate continued expansion. With demand up 12% in August and positive product margins despite housing market challenges, RH&#8217;s luxury positioning remains strong. <strong><span style=\"color: #0000ff;\">Their 2024 P\/E of 161.56 has been keeping people away, but ongoing international expansion could justify the multiple next year<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=rh%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>RIO ($78) \u2013 Now at $62.55, RIO trades at an attractive P\/E of 9.5 with EPS of $6.58. Despite trading below both 50-day ($65.54) and 200-day ($65.79) moving averages, analyst consensus remains bullish with an average price target of $83.25. Their diversified mining portfolio and strategic position in materials essential for green energy transition provide long-term value. <strong><span style=\"color: #0000ff;\">The stock offers significant upside potential according to analyst forecasts, with estimates ranging from $77 to $95 per share<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=rio%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>SKX ($63.82)<\/strong><\/span> &#8211; We already have them but currently showing strong fundamentals in the athletic footwear segment with consistent growth in both domestic and international markets. Their focus on comfort technology and value pricing provides competitive advantages in the growing casual footwear market. Trading at attractive multiples with strong brand recognition and global expansion opportunities, SKX&#8217;s market position and operational efficiency suggest significant upside potential for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=skx&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>SLB ($43.63)<\/strong><\/span> &#8211; Currently trading at a 40% discount to fair value with the largest global market share in oilfield services. Their innovative technology focus, with 20% of annual revenue from new tech, and dominant position in wireline services provide competitive advantages. Trading at attractive multiples with a 2.56% dividend yield, SLB&#8217;s strong balance sheet and high exposure to non-US markets suggest significant upside potential. Their efficiency gains and market leadership in multiple categories provide clear catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=slb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SOFI ($6.23) \u2013 Currently at $14.50, SOFI has finally shown the growth we expected, up 133% from our initial watch price. Q3 2024 results demonstrated strong fundamentals with total customers growing 35% year-over-year to 9.4 million and adjusted net revenue up 30%. Their financial services segment is approaching the $1 billion annualized revenue mark, and management expects to add at least 2.3 million new members. With net income of $61 million last quarter and projected $200 million for fiscal year 2024, SOFI has achieved profitability ahead of schedule.\u00a0The recent addition of robo-advisory services and a $2 billion loan deal with Fortress Investment Group shows continued innovation and business model evolution.<span class=\"animate-in fade-in-25 duration-700\">.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=sofi%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SONY ($89) \u2013 Trading at $19.27 (post 5:1 split), SONY reported impressive Q2 FY2024 results with operating income increasing 73% to 455.1 billion yen. Their diverse revenue streams across Music, Electronics Products &amp; Solutions, and Gaming &amp; Network Services segments showed strong growth, though Pictures and Financial Services segments experienced some decline.\u00a0The company&#8217;s strategic positioning across entertainment, gaming, and electronics continues to demonstrate resilience, with particularly strong performance in their Music and Gaming divisions.\u00a0\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=sony%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SPG ($124) \u2013 Now at $180.50, SPG continues to show operational strength with Q3 2024 occupancy rates reaching 96.2%, up 1% from 95.2% in 2023. Base minimum rent increased 2.3% to $57.71 per square foot. The company signed approximately 1,200 new leases this quarter, including 75 new luxury deals covering 208,000 square feet. Their successful expansion continues with new openings like Tulsa Premium Outlets and Busan Premium Outlets. Management remains optimistic about consumer spending, particularly noting strength in the higher-end segment.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=spg%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SWK ($86) \u2013 Currently at $86.21, SWK reported Q3 2024 with improving gross margins and strong cash generation, though organic revenue faced headwinds from weak consumer demand. Their sixth consecutive quarter of DEWALT growth and higher aerospace fastener sales provide bright spots. The company remains focused on supply chain transformation, targeting 35%+ adjusted gross margins.\u00a0Trading at a negative P\/E of -69.51 due to recent losses, SWK&#8217;s transformation efforts and focus on core brands show promise, though near-term challenges persist.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=swk%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SYF ($35.40) \u2013 Trading at $64.41, SYF continues its impressive run with Q3 2024 adjusted EPS of $1.94, beating estimates of $1.77. Net interest income grew 5.7% year-over-year to $4.6B, with improved efficiency ratio of 31.2%. Their strong balance sheet shows $22.4B in total liquidity and return on equity rose to 19.8%. Management raised 2024 EPS guidance to $8.45-$8.55, reflecting operational strength. <strong><span style=\"color: #0000ff;\">At a P\/E of 8.36, SYF remains attractively valued despite significant price appreciation<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=syf&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>T ($19.23) \u2013 Now at $22.81, T shows improved performance with a P\/E of 18.54. Their strategic focus on 5G infrastructure and fiber deployment continues, with plans to deploy Open RAN for 70% of wireless network traffic by late 2026. While earnings estimates for 2024 have been revised downward, their fiber customer growth and network modernization efforts position them well for long-term growth. The stock has outperformed industry averages over the past year, though near-term earnings challenges remain.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=t%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TGT ($162) \u2013 Currently at $121.34, TGT JUST reported disappointing Q3 2024 results with revenue of $25.67B, missing estimates of $25.89B. Net income fell to $854M ($1.85 per share) from $971M ($2.10) a year ago. The company lowered its full-year EPS guidance to $8.30-$8.90 from $9.00-$9.70. While customer traffic increased 2.4% and digital sales grew 10.8%, comparable store sales declined 1.9%. The stock has plunged over 21% on the news, reaching a 52-week low. Despite these challenges, their focus on price competitiveness and strong beauty segment performance could provide future catalysts &#8211; but no hurry.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=tgt%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TNDM ($42.70) \u2013 Trading at $29.08, TNDM showed strong Q3 2024 performance with worldwide sales increasing 31% to $244.0M. Their pump shipments grew by more than 25% year-over-year, with increased adoption in both U.S. and international markets. While still reporting a net loss of $23.3M (improved from $33.0M loss last year), they achieved positive Adjusted EBITDA of $4.0M. The company raised its full-year 2024 sales guidance to $903-910M, demonstrating confidence in their growth trajectory but Trump\/Kennedy make them a dangerous play.\u00a0\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=tndm%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TROX ($16.50) \u2013 Now at $11.38, TROX continues to face challenges with weak titanium products demand (China). Trading at a negative P\/E of -24.21 due to recent losses, the company maintains a 4.6% dividend yield though the 188% payout ratio raises sustainability concerns. Their market cap has declined to $1.8B, with the stock down 23.33% over the past 11 months. While their vertically integrated manufacturing model provides some advantages, near-term headwinds persist in the titanium dioxide market. Still, <strong><span style=\"color: #0000ff;\">their strong niche position makes them a solid long-term play<\/span><\/strong>.\u00a0\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=trox%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TRVG ($1.66) \u2013 Currently at $1.67, TRVG reported disappointing Q3 2024 results with revenue declining 7% to \u20ac146.1M compared to Q3 2023. Their Rest of World segment showed 9% growth, but Developed Europe dropped 8% and Americas declined 14%. The company maintains a strong cash position of \u20ac108M with net working capital around \u20ac140M. Their strategic focus on AI-powered highlights for 250,000 hotels shows innovation, but current market conditions and Google ad format changes continue to pressure performance. The negative P\/E of -4.51 reflects ongoing challenges.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=trvg%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TWO ($17.78) \u2013 Trading at $11.77, TWO reported Q3 2024 comprehensive income of $19.3M ($0.18 per share). The company maintains a quarterly dividend of $0.45 per share with book value at $14.93. Their portfolio includes $11.4B in Agency RMBS, MSR, and other securities, plus $5.0B in TBA positions. Recent MSR acquisitions of $3.3B and commitment to purchase an additional $2.1B UPB demonstrate continued growth. Their first full quarter of direct-to-consumer originations shows business model evolution, though the negative P\/E of -2.45 reflects recent challenges.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=two%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>UHS ($150) \u2013 Now at $198.28, UHS showed strong Q3 2024 performance with net income of $258.7M ($3.80 per diluted share), up from $167.0M ($2.40) in Q3 2023. Net revenues increased 11.2% to $3.96B. The company recently declared a quarterly dividend of $0.20 per share, payable December 17, 2024. Their acute care segment showed healthy growth with adjusted admissions up 1.5% and net revenue per adjusted admission increasing 7.0%. <strong><span style=\"color: #0000ff;\">Trading at 13.23x earnings, UHS demonstrates solid operational execution and financial stability<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=uhs&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>USB ($52.77)<\/strong><\/span> &#8211; Currently trading at a 10% discount to fair value with one of the strongest profitability records among regional banks. Their unique mix of fee-generating businesses, including payments, corporate trust, and wealth management, provides diverse revenue streams without investment banking risk. Trading at attractive multiples with exemplary capital allocation, USB&#8217;s payments ecosystem expansion and strategic acquisitions suggest significant upside potential. Their national scale and proven management team provide clear catalysts for 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=usb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>VALE ($18) \u2013 Currently at $9.98, VALE&#8217;s disappointing 2024 performance stems from multiple factors. Their iron ore production fell 6.3% in Q3 2024, while China&#8217;s property sector crisis and broader economic slowdown severely impacted demand. The company&#8217;s 2024 Trade of the Year thesis was undermined by weaker-than-expected Chinese infrastructure spending and persistent legal challenges from the Brumadinho dam disaster. Looking ahead to 2025, Vale&#8217;s prospects hinge on their cost reduction initiatives and potential Chinese stimulus measures. Their focus on high-grade iron ore production and expanding copper operations could provide catalysts, though Chinese property sector recovery remains crucial for significant price appreciation.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=vale&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>VTRS ($9.18) \u2013 Trading at $13.40, VTRS has shown impressive momentum in 2024, up 46% from our initial watch price. Q3 2024 results exceeded expectations with total revenues of $3.94B and adjusted EBITDA of $1.27B. Their debt reduction strategy continues to succeed, having paid down $1.4B in debt year-to-date. The company&#8217;s expansion into complex generics and biosimilars, combined with strategic partnerships in emerging markets, positions them well for continued growth. <strong><span style=\"color: #0000ff;\">Trading at just 4.2x forward earnings, VTRS remains attractively valued despite recent appreciation<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=vtrs&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>VZ ($43.85)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals with Q3 2024 wireless segment demonstrating margin expansion of 0.5% to 40.9%. Their network coverage reaches 98% of the U.S. with strategic 5G deployment continuing. Trading at attractive valuations with an 11.4% expected annual return over the next five years, VZ&#8217;s focus on network quality and operational efficiency provide clear catalysts. Their consistent cash flow generation and potential market share gains suggest stronger performance in 2025.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=vz&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>WBA ($36) \u2013 Now at $8.53, WBA faces significant challenges with their VillageMD investment defaulting on a $2.25B secured loan facility. The company is exploring options including a potential sale of all or part of VillageMD following substantial losses. Their strategic review aims to simplify their U.S. Healthcare portfolio and enhance liquidity. Recent management changes and a 48% dividend cut reflect the severity of their challenges. While trading at historically low valuations, WBA&#8217;s transformation efforts and VillageMD complications create significant near-term uncertainty.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=wba&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>WHR ($150) \u2013 Currently at $112.32, WHR reported challenging Q3 2024 results with net sales of $4B, down 18.9% year-over-year. However, they achieved sequential EBIT margin expansion with ongoing EPS of $3.43, and their adjusted EBITDA margin improved by 50 basis points globally. Their focus on cost reduction continues, targeting $300M in cost takeouts for the full year. <strong><span style=\"color: #0000ff;\">While facing near-term headwinds, their strategic positioning for an eventual U.S. housing market recovery and strong product pipeline, including new Whirlpool brand laundry innovations, provide potential catalysts<\/span><\/strong>. The company maintains its full-year ongoing EPS guidance of approximately $12.00.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=whr&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>XRX ($17) \u2013 Trading at $9.18, XRX faces significant challenges with Q3 2024 revenue declining 7.5% to $1.53B. The company reported a GAAP net loss of $1.2B, including a $1B non-cash goodwill <strong>impairment<\/strong> charge<span class=\"whitespace-nowrap\">.<\/span>\u00a0Equipment sales dropped 12.2%, though adjusted operating margin improved 110 basis points to 5.2%<span class=\"whitespace-nowrap\">.<\/span>\u00a0Management has lowered 2024 guidance, now expecting revenue to decline around 10% in constant currency<span class=\"whitespace-nowrap\">.<\/span>\u00a0While operational improvements from their Reinvention initiatives show promise, the significant reduction in guidance and ongoing market challenges suggest continued pressure.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=xrx&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>YETI ($43) \u2013 Now at $39.71, YETI demonstrated strong Q3 2024 performance with revenue up 10% to $478.4M and net income increasing 32% to $56.3M. Their profit margin expanded to 12% from 9.8%, with particular strength in Coolers &amp; Equipment (up 12%) and international sales soaring 30%. The company&#8217;s strategic focus on product innovation and international expansion continues to drive growth, with management raising full-year guidance. <strong><span style=\"color: #0000ff;\">Trading at 17.13x earnings with projected 6.9% annual revenue growth over the next three years, YETI maintains strong momentum despite market challenges<\/span><\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=yeti&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We&#8217;re looking for our 2025 Trade of the Year.\u00a0\u00a0 Our last Watch List was published on July 10th, following up on our main list (like this one) from Dec 27th, 2023 and now it&#8217;s time to take a long hard look at what stocks are still buyable &#8211; and it&#8217;s going to be a short [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":12464627,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,11],"tags":[],"class_list":{"0":"post-12750830","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-available","8":"category-portfolio-review"},"_links":{"self":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts\/12750830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/comments?post=12750830"}],"version-history":[{"count":11,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts\/12750830\/revisions"}],"predecessor-version":[{"id":12788111,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts\/12750830\/revisions\/12788111"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/media\/12464627"}],"wp:attachment":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/media?parent=12750830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/categories?post=12750830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/tags?post=12750830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}